.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Citi
Healthtrust
Accenture
Cipla
AstraZeneca
Cerilliant
Chinese Patent Office
Novartis

Generated: September 20, 2017

DrugPatentWatch Database Preview

Trimetrexate glucuronate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for trimetrexate glucuronate and what is the scope of trimetrexate glucuronate patent protection?

Trimetrexate glucuronate
is the generic ingredient in one branded drug marketed by Medimmune Oncology and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Trimetrexate glucuronate has six patent family members in six countries.

There is one drug master file entry for trimetrexate glucuronate.

Summary for Generic Name: trimetrexate glucuronate

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Drug Master File Entries: see list1
Bulk Api Vendors: see list8
Clinical Trials: see list17
Patent Applications: see list3,230
Therapeutic Class:Antiparasitics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:trimetrexate glucuronate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medimmune Oncology
NEUTREXIN
trimetrexate glucuronate
INJECTABLE;INJECTION020326-002Jul 31, 1998DISCNNoNo► Subscribe► Subscribe ► Subscribe
Medimmune Oncology
NEUTREXIN
trimetrexate glucuronate
INJECTABLE;INJECTION020326-001Dec 17, 1993DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: trimetrexate glucuronate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medimmune Oncology
NEUTREXIN
trimetrexate glucuronate
INJECTABLE;INJECTION020326-001Dec 17, 1993► Subscribe► Subscribe
Medimmune Oncology
NEUTREXIN
trimetrexate glucuronate
INJECTABLE;INJECTION020326-001Dec 17, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: trimetrexate glucuronate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,258,952 Thermally stable trimetrexates and processes for producing the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: trimetrexate glucuronate

Country Document Number Estimated Expiration
Brazil9910543► Subscribe
European Patent Office1080079► Subscribe
Canada2333274► Subscribe
Australia4081799► Subscribe
World Intellectual Property Organization (WIPO)9959981► Subscribe
Japan2002515493► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Chinese Patent Office
Fish and Richardson
Argus Health
Covington
McKesson
Daiichi Sankyo
Medtronic
Farmers Insurance
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot